Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 2549 • ACR Convergence 2023
Effect of Ixekizumab Treatment on MRI Structural Lesions in the Sacroiliac Joints of Patients with Radiographic Axial Spondyloarthritis; A Post-hoc Analysis of a Placebo and Active Controlled RCT
Walter P. Maksymowych¹, Robert Lambert², Eswar Krishnan³, Baojin Zhu³, Rebecca Bolce³ and Mikkel Østergaard⁴, ¹University of Alberta, Edmonton, AB, Canada, ²Department of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada, ³Eli Lilly and Company, Indianapolis, IN, ⁴Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark
Background/Purpose: The effect of Ixekizumab (IXE) on structural lesions in the sacroiliac joints (SIJ) of patients (pts) with radiographic Axial Spondylarthritis (r-axSpA) assessed by magnetic…
Abstract Number: L14 • ACR Convergence 2022
Bimekizumab Maintains Improvements in Efficacy Endpoints and Has a Consistent Safety Profile Through 52 Weeks in Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis: Results from Two Parallel Phase 3 Studies
Xenofon Baraliakos¹, Atul Deodhar², Désirée van der Heijde³, Marina Magrey⁴, Walter Maksymowych⁵, Tetsuya Tomita⁶, Huji Xu⁷, Marga Oortgiesen⁸, Ute Massow⁹, Carmen Fleurinck¹⁰, Alicia M Ellis⁸, Tom Vaux¹¹, Julie Shepherd-Smith¹¹, Alexander Marten⁹ and Lianne S Gensler¹², ¹Rheumazentrum Ruhrgebiet, Herne, Ruhr-Universität Bochum, Bochum, Nordrhein-Westfalen, Germany, ²Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, US, Richfield, OH, ⁵Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁶Graduate School of Health Science, Morinomiya University of Medical Science, Osaka City, Osaka City, Osaka, Japan, ⁷Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, Affiliated to Second Military Medical University, Shanghai, China (People's Republic), ⁸UCB Pharma, Morrisvile, NC, ⁹UCB Pharma, Monheim am Rhein, Nordrhein-Westfalen, Germany, ¹⁰UCB Pharma, Brussels, Brussels Hoofdstedelijk Gewest, Belgium, ¹¹UCB Pharma, Slough, United Kingdom, ¹²Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL‑17A. In the phase 3 BE MOBILE 1 and 2…
Abstract Number: 0385 • ACR Convergence 2022
T Cell Receptor Sequencing Identifies Two Classes of T Cells Enriched in HLA-B27-associated Inflammation
Michael Paley¹, Lynn Hassman², Grace Paley², Nicole Linskey², Philip Ruzycki², Jennifer Laurent², Lacey Feigl², Luke Springer² and Wayne Yokoyama², ¹Washington University in St. Louis, Saint Louis, MO, ²Washington University School of Medicine, St. Louis, MO
Background/Purpose: HLA-B27 is genetically linked to Axial Spondyloarthritis (axSpA) and anterior uveitis (AU), an inflammatory ocular disease that can lead to cataract, glaucoma, and permanent…
Abstract Number: 0415 • ACR Convergence 2022
The Association of Early TNF Inhibitor Use with Incident Cardiovascular Events in Ankylosing Spondylitis
Jean Liew¹, Timothy Treu², yojin Park², Jacqueline Ferguson³, Morgan Rosser², yuk-Lam Ho², Susan Heckbert⁴, Lianne Gensler⁵, Katherine Liao⁶ and Maureen Dubreuil⁷, ¹Boston University School of Medicine, Boston, MA, ²VA Boston Healthcare System, Boston, MA, ³Stanford, Palo Alto, CA, ⁴University of Washington, Seattle, WA, ⁵Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Department of Rheumatology, Boston University School of Medicine, Boston, MA
Background/Purpose: The increased cardiovascular (CV) disease burden in ankylosing spondylitis (AS) is established. Whether tumor necrosis factor inhibitor (TNFi) treatment, particularly when started early in…
Abstract Number: 1010 • ACR Convergence 2022
Comparison of Established and New, Preliminarily Proposed ASAS Cut-Offs for Inflammatory MRI Lesions in the Sacroiliac Joints of Axial Spondyloarthritis Patients and Implications for Recruitment in Clinical Studies
Xenofon Baraliakos¹, Pedro Machado², Lars Bauer³, Bengt Hoepken³, Mindy Kim⁴, Thomas Kumke³, Rachel Tham⁵ and Martin Rudwaleit⁶, ¹Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ²University College London, London, United Kingdom, ³UCB Pharma, Monheim am Rhein, Germany, ⁴UCB Pharma, Smyrna, GA, ⁵UCB Pharma, Slough, UK, Overland Park, KS, ⁶University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium
Background/Purpose: The Assessment of SpondyloArthritis international Society (ASAS) recently proposed preliminary, more stringent, data-driven definitions for active and structural MRI lesions of the sacroiliac joint…
Abstract Number: 1163 • ACR Convergence 2022
Proteomic Investigation to Identify Urinary Biomarker for Ankylosing Spondylitis
Ji-Hyun Lee¹, Jeesoo Kim², Sang-Hyon kim¹, Jong‑Seo kim² and Chang-Nam son¹, ¹Keimyung University, Dalseo-gu, Daegu, Republic of Korea, ²seoul national university, Seoul, Republic of Korea
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease that affects the spine and peripheral joints, and the exact etiology is still unknown. Diagnosis…
Abstract Number: 2254 • ACR Convergence 2022
Detection of Active Inflammatory and Structural Changes Indicative of Axial Spondyloarthritis on MRI of Sacroiliac Joint Using a Deep Learning Framework
Keno Kyrill Bressem¹, Lisa Adams¹, Fabian Proft², Kay-Geert Hermann³, Torsten Diekhoff¹, Laura Spiller¹, Stefan Niehues¹, Marcus Makowski⁴, Bernd Hamm¹, Mikhail Protopopov⁵, valeria Rios-Rodriguez⁶, Hildrun Haibel⁷, Judith Rademacher⁵, Murat Torgutalp⁷, Robert G Lambert⁸, Xenofon Baraliakos⁹, Walter P Maksymowych¹⁰, Janis Vahldiek¹ and Denis Poddubnyy², ¹Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ³Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Technical University of Munich, Munich, Germany, ⁵Charité Universitätsmedizin Berlin, Berlin, Germany, ⁶Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁷Charité - Universitätsmedizin, Berlin, Berlin, Germany, ⁸University of Alberta, Edmonton, AB, Canada, ⁹Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ¹⁰Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Magnetic resonance tomography (MRI) plays a key role in the early diagnosis of axial spondyloarthritis (axSpA). However, the detection of changes indicative of axSpA…
Abstract Number: 0386 • ACR Convergence 2022
Quantitative Proteomic Screening Uncovers Diagnostic and Monitoring Serum Biomarkers of Ankylosing Spondylitis
Mark Hwang¹, Jessica Castillo², kamala Vanarsa², Jim Zheng³, Shervin Assassi⁴, Chandra Mohan² and John Reveille⁵, ¹McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ²University of Houston, Houston, TX, ³UTHealth School of Bioinformatics, Houston, TX, ⁴McGovern Medical School, University of Texas, Houston, TX, ⁵University of Texas McGovern Medical School, Houston, TX
Background/Purpose: We sought to discover novel serum biomarkers of ankylosing spondylitis (AS) for diagnosis and monitoring disease activity. Methods: We used biologic-treatment naïve AS and…
Abstract Number: 0416 • ACR Convergence 2022
Efficacy and Safety of Biological DMARDs: A Systematic Literature Review Informing the 2022 Update of the ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis
Casper Webers¹, Augusta Ortolan², Alexandre Sepriano³, Louise Falzon⁴, Xenofon Baraliakos⁵, Robert Landewé⁶, Sofia Ramiro⁷, Désirée van der Heijde⁸ and Elena Nikiphorou⁹, ¹Maastricht University Medical Centre, Maastricht, Netherlands, ²University of Padova/Leiden University Medical Center, Padova, Italy, ³Leiden University Medical Centre, Portela Loures, Portugal, ⁴Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom, ⁵Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ⁶Amsterdam University Medical Center, Meerssen, Netherlands, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ⁹Leiden University Medical Center & King's College London, London, United Kingdom
Background/Purpose: Since the 2016 update of the management recommendations for axial spondyloarthritis (axSpA), new evidence has emerged on the efficacy and safety of biological disease-modifying…
Abstract Number: 1011 • ACR Convergence 2022
Trends in Fracture Rates Among Veterans with Ankylosing Spondylitis
Sali Merjanah¹, Jean Liew¹, John Bihn², Nathanael Fillmore², Nhan Do³ and Maureen Dubreuil⁴, ¹Boston University, Boston, MA, ²VA Boston Healthcare System, Boston, MA, ³VA Boston Healthcare System, Boston University School of Medicine, Boston, MA, ⁴Department of Rheumatology, Boston University School of Medicine, Boston, MA
Background/Purpose: A meta-analysis demonstrated that the risk of vertebral fractures in Ankylosing Spondylitis (AS) is doubled compared to non-AS comparators. Increased fracture risk in AS…
Abstract Number: 1248 • ACR Convergence 2022
A Retrospective Chart Review Examining How a Change in MRI Protocol Could Affect the Diagnosis of Axial Spondyloarthritis
Alexa Kouroukis¹, Manisha Mulgund², Leilani Famorca³, Pauline Boulos¹ and Viktoria Pavlova⁴, ¹McMaster University, Hamilton, ON, Canada, ²Trillium Health Partners, Ancaster, ON, Canada, ³McMaster University, Milton, ON, Canada, ⁴McMaster University, Ancaster, ON, Canada
Background/Purpose: St. Joseph's Healthcare Hamilton (SJHH) recently changed their MRI-axial spondyloarthritis (axSpA) protocol, used to diagnose patients with axSpA, from an MRI of the spine…
Abstract Number: 2255 • ACR Convergence 2022
Do Fatty Lesions Explain the Association Between Inflammation and New Syndesmophytes in Patients with Radiographic Axial Spondyloarthritis?
Rosalinde Stal¹, Alexandre Sepriano², Sofia Ramiro¹, floris van Gaalen¹, Pedro Machado³, Xenofon Baraliakos⁴, Manouk de Hooge⁵, Rosaline van den Berg¹, Monique Reijnierse¹, Juergen Braun⁶, Robert Landewé⁷ and Désirée van der Heijde⁸, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Centre, Portela Loures, Portugal, ³University College London, London, United Kingdom, ⁴Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ⁵Ghent University Hospital, Luxembourg, Luxembourg, ⁶Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷Amsterdam University Medical Center, Meerssen, Netherlands, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands
Background/Purpose: Presence of vertebral corner inflammation (VCI) increases the likelihood of a new syndesmophyte in the same vertebral corner (VC) in patients with r-axSpA. It…
Abstract Number: 0388 • ACR Convergence 2022
Incidence Rate and Factors Associated with Fractures Among Older Adults with Ankylosing Spondylitis in the United States
Rachael Stovall¹, Emma Kersey¹, Jing Li², Rahaf Baker³, Christine Anastasiou², Gabriela Schmajuk⁴, Lianne Gensler⁵ and Jinoos Yazdany⁶, ¹University of California San Francisco, San Francisco, CA, ²University of California, San Francisco, San Francisco, CA, ³Alameda Highland Internal Medicine Residency, Oakland, CA, ⁴UCSF / SFVA, San Francisco, CA, ⁵Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA, ⁶UCSF, San Francisco, CA
Background/Purpose: Adults with ankylosing spondylitis (AS) are at a significantly increased risk of fracture relative to the general population. While some studies have evaluated the…
Abstract Number: 0418 • ACR Convergence 2022
Real World Evidence on Disease Activity in Patients with Ankylosing Spondylitis Treated with Tumour Necrosis Factor Inhibitors and/or Nonsteroidal Anti-Inflammatory Drugs in Routine Care
Jan Brandt-Juergens¹, Judith Haschka², Richard Finsterwalder³, Aurélie Casier⁴, Angela Kill⁵ and Stéphanie Dierckx⁶, ¹Rheumatologische Schwerpunktpraxis, Berlin, Germany, ²Karl Landsteiner Institute for Gastroenterology and Rheumatology Rheuma-Zentrum Wien-Oberlaa, Vienna, Austria, ³Novartis Pharma GmbH, Vienna, Austria, ⁴N.V. Novartis Pharma S.A., Vilvoorde, Belgium, ⁵Novartis Pharma GmbH, Nuremberg, Germany, ⁶CHU UCL Namur- Site Godinne, Yvoir, Belgium
Background/Purpose: Ankylosing Spondylitis (AS) is an inflammatory rheumatic disease affecting the axial skeleton (1), with a prevalence of up to 0.5% in Europe (2; 3),…
Abstract Number: 1025 • ACR Convergence 2022
Entheseal Biopsy Approach: An Ultrasound-guided Method for Retrieval of Entheseal Tissue from Psoriatic Arthritis Patients
Maria Gabriella Raimondo¹, Milena Pachowsky¹, Cong Xu¹, Simon Rauber¹, Koray Tascilar¹, Hannah Labinsky², Mario Vogg¹, Mina Saad Aziz Saad¹, David Simon¹, Juergen Rech³, Alina Soare¹, Lars Braeuer⁴, Arnd Kleyer¹, Georg Schett⁵ and Andreas Ramming¹, ¹Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ²Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ³University Clinic Erlangen, Erlangen, Germany, ⁴Institute of Anatomy, Chair II, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Germany, ⁵Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: Enthesitis as hallmark feature of psoriatic arthritis (PsA) has been mostly addressed through clinical assessment and imaging evaluation, such as MRI or musculoskeletal ultrasound.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].